Amgen, Inc. (AMGN) Shares Sold by Sigma Planning Corp

Sigma Planning Corp decreased its position in shares of Amgen, Inc. (NASDAQ:AMGN) by 17.3% in the third quarter, Holdings Channel reports. The fund owned 14,822 shares of the medical research company’s stock after selling 3,106 shares during the period. Sigma Planning Corp’s holdings in Amgen were worth $2,764,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently added to or reduced their stakes in the business. Baker Ellis Asset Management LLC bought a new position in shares of Amgen during the 3rd quarter worth about $108,000. Jackson Grant Investment Advisers Inc. increased its holdings in shares of Amgen by 0.8% during the 2nd quarter. Jackson Grant Investment Advisers Inc. now owns 641 shares of the medical research company’s stock worth $110,000 after purchasing an additional 5 shares during the period. Phocas Financial Corp. bought a new position in shares of Amgen during the 2nd quarter worth about $110,000. Omnia Family Wealth LLC increased its holdings in shares of Amgen by 25.3% during the 2nd quarter. Omnia Family Wealth LLC now owns 729 shares of the medical research company’s stock worth $125,000 after purchasing an additional 147 shares during the period. Finally, Grove Bank & Trust increased its holdings in shares of Amgen by 87.4% during the 2nd quarter. Grove Bank & Trust now owns 731 shares of the medical research company’s stock worth $126,000 after purchasing an additional 341 shares during the period. 78.48% of the stock is owned by hedge funds and other institutional investors.

Shares of Amgen, Inc. (NASDAQ AMGN) opened at $185.04 on Tuesday. The firm has a market cap of $134,322.48, a PE ratio of 16.75, a P/E/G ratio of 2.70 and a beta of 1.36. Amgen, Inc. has a 52 week low of $150.38 and a 52 week high of $191.10. The company has a debt-to-equity ratio of 1.05, a current ratio of 6.07 and a quick ratio of 5.72.

Amgen (NASDAQ:AMGN) last posted its earnings results on Wednesday, October 25th. The medical research company reported $3.27 earnings per share for the quarter, beating the Zacks’ consensus estimate of $3.11 by $0.16. The business had revenue of $5.77 billion for the quarter, compared to analysts’ expectations of $5.75 billion. Amgen had a net margin of 35.54% and a return on equity of 29.90%. The firm’s revenue for the quarter was down .7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $3.02 earnings per share. equities analysts expect that Amgen, Inc. will post 12.71 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 8th. Investors of record on Thursday, February 15th will be paid a $1.32 dividend. The ex-dividend date is Wednesday, February 14th. This represents a $5.28 dividend on an annualized basis and a yield of 2.85%. This is a boost from Amgen’s previous quarterly dividend of $1.15. Amgen’s payout ratio is presently 41.63%.

Amgen announced that its Board of Directors has authorized a stock buyback program on Wednesday, October 25th that permits the company to buyback $5.00 billion in outstanding shares. This buyback authorization permits the medical research company to purchase shares of its stock through open market purchases. Shares buyback programs are usually a sign that the company’s management believes its shares are undervalued.

Several research analysts have recently issued reports on the stock. Mizuho set a $192.00 price objective on shares of Amgen and gave the stock a “buy” rating in a report on Friday, December 22nd. Zacks Investment Research downgraded shares of Amgen from a “buy” rating to a “hold” rating in a report on Monday, October 30th. Royal Bank of Canada dropped their price objective on shares of Amgen from $192.00 to $188.00 and set a “sector perform” rating on the stock in a report on Thursday, October 26th. Credit Suisse Group restated a “neutral” rating and set a $186.00 price objective (up previously from $177.00) on shares of Amgen in a report on Friday, September 29th. Finally, Oppenheimer restated a “buy” rating and set a $205.00 price objective on shares of Amgen in a report on Thursday, November 30th. One investment analyst has rated the stock with a sell rating, fourteen have issued a hold rating and ten have given a buy rating to the company. Amgen has a consensus rating of “Hold” and an average price target of $190.15.

In other Amgen news, Director Carbonnel Francois De sold 4,000 shares of the company’s stock in a transaction dated Wednesday, November 8th. The shares were sold at an average price of $173.61, for a total transaction of $694,440.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Sean E. Harper sold 1,525 shares of the company’s stock in a transaction dated Tuesday, December 12th. The stock was sold at an average price of $176.83, for a total transaction of $269,665.75. Following the sale, the executive vice president now directly owns 56,106 shares in the company, valued at $9,921,223.98. The disclosure for this sale can be found here. In the last three months, insiders sold 7,050 shares of company stock worth $1,225,765. 0.19% of the stock is currently owned by insiders.

TRADEMARK VIOLATION WARNING: This report was posted by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this report on another site, it was copied illegally and republished in violation of United States & international copyright and trademark law. The original version of this report can be viewed at https://sportsperspectives.com/2018/01/16/amgen-inc-amgn-shares-sold-by-sigma-planning-corp.html.

Amgen Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply